Chronic portfolio stabilizes as acute care drives steady growth
- Option Care Health sells infusion care in homes and alternate sites, providing a lower-cost setting than many hospital visits.
- Management notes its national reach covers 96% of the U.S. population.
- Q2 2026 results showed the chronic portfolio stabilizing with sequential patient census growth.
- The company maintained its gross profit headwind estimate of roughly $55 million for the year.
- Ambulatory infusion clinics are a rising bright spot, with visits growing more than 20% year over year.
Signs of stability emerge after a tough start to the year
The bull case focuses on the acute segment, which continues to deliver high single-digit growth above market rates. This performance validates the local network and hospital partnerships. Furthermore, the chronic portfolio began to stabilize in Q2 2026, with the patient census rising sequentially. The rapid growth of ambulatory infusion clinics, where visits are up over 20% year over year, offers another avenue for margin expansion.
However, the bear case still carries weight. The chronic portfolio remains burdened by an expected $55 million gross profit headwind for 2026, a lingering effect of earlier patient census resets and unfavorable therapy mix. The company remains highly reliant on sustained above-market performance in the acute segment to offset these chronic pressures.
Investors should watch the planned rollout of new rare and orphan therapies in late 2026 and early 2027. Any execution missteps in launching this pipeline could push growth out further, putting additional strain on the core business segments.
Paid to move infusions out of hospitals
Option Care provides infusion care at home and in alternate sites. Patients receive complex drugs through an IV or similar method outside a hospital when clinically appropriate. The primary goal is delivering lower costs for payers, more comfort for patients, and broad clinical reach for drug makers.
The company earns revenue through reimbursement for the drug, clinical per diems, and nursing services. Scale is a major advantage. The network covers nearly the entire country and includes a large nursing footprint supporting care delivery.
This model can suffer when drug economics change faster than expected or when payers tighten rules. The ongoing headwind in the chronic portfolio demonstrates how elongated benefit authorizations and unfavorable therapy mix can quickly erode gross profit.
A broad basket of infusion therapies
Acute infusion therapies
This category includes mature therapies such as intravenous antibiotics and nutrition support. The segment is delivering high single-digit growth.
Chronic infusion therapies
Chronic therapies form the largest part of the business. The segment experienced a severe reset early in 2026 but showed sequential patient census growth in the second quarter.
Rare, orphan, and limited distribution drugs
These newer therapies are a key growth driver, with new additions slated to launch in late 2026 and early 2027.
Ambulatory infusion clinics
A rapidly growing footprint of physical clinic locations for patients, with visits expanding more than 20% year over year.
Biosimilar-exposed therapies
The portfolio includes therapies facing biosimilar changes, though management estimates that Stelara and related biosimilars will represent less than 1% of 2026 net revenue.
Chronic therapies drive the majority of revenue
The mix relies on historical management commentary that chronic typically represents roughly 75% of revenue and acute 25%.
What could go wrong
Chronic portfolio gross profit headwinds
High impact · High oddsManagement maintained a 2026 gross profit headwind estimate of about $55 million due to severe patient census resets and unfavorable therapy mix in the CID portfolio.
Delayed rare and orphan launches
Medium impact · Medium oddsThe company relies on a pipeline of rare and orphan therapies to drive top-line growth. Delays in the commercial go-live of these therapies could hurt expected growth rates.
Acute segment growth fades
Medium impact · Medium oddsThe acute segment has carried the growth load with high single-digit expansion. If this segment slows, the company will have a hard time offsetting chronic portfolio weakness.
Payer and authorization pressure
High impact · Medium oddsInsurance plan changes and elongated benefit reauthorizations previously caused unexpected weakness. Tightening payer requirements can squeeze profits quickly.
In one breath
What does Option Care Health do?
Option Care Health provides infusion care outside the hospital, mainly in homes and alternate sites. Patients receive complex therapies with support from pharmacists, nurses, and clinical teams.
How does OPCH make money?
The company is reimbursed by payers for the drug, clinical per diems, and nursing services. Its goal is to deliver the same needed therapy in a lower-cost setting than a hospital.
Why is the chronic portfolio struggling?
The company faced a severe reset in its CID patient census due to insurance plan changes and longer reauthorization times, creating a $55 million gross profit headwind for 2026. However, it recently began to stabilize.
What should investors watch next?
Investors should watch whether the CID patient base continues to grow sequentially and if management can successfully launch new rare and orphan programs slated for late 2026.
